Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Market cap at $1.1B.
( List compiled by Kapitall Contributor Chris Lau )
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.